FDA Recall United States TerminatedTerminated: April 30, 2020Historical recordClass III
Wilton Brands
- Product
- Wilton Chocolate decorator icing stiff consistency 16 oz…
- Reason
- Mold
- Published
- July 24, 2019
- Distribution
- AL AR AZ CA CO CT DE FL GA IA…
Data Explorer
Research historical outbreak investigations and the full recall archive, with charts, trends, and advanced filters. Looking for what's happening right now instead? See current Health Alerts.
Recall totals
All FDA and USDA recalls in Public Health Trace, June 2012 to November 2026.
37,449
Total recall recordsAll FDA and USDA recalls in Public Health Trace9,872
Class I recallsReasonable probability of serious health consequences24,509
Class II recallsTemporary or medically reversible health consequences2,932
Class III recallsNot likely to cause adverse health consequencesQuick insights
A snapshot of the most notable patterns across all recorded FDA and USDA recalls.
Most recalled product100 vegetarian Fenugreek Capsules 90 count, 600mg, packaged in 150cc Amber Glass Packer with White Polypropylene Cap.
53 recalls
Most common hazardLack of Assurance of Sterility
2,096 recalls
Newest recallhttps://www.fsis.usda.gov/recalls-alerts/fsis-issues-public-health-alert-meat-and-poultry-products-due-misbranding-andPublished November 6, 2026
Download matching recalls as CSV
CSV exports include up to 5,000 matching rows (applying your current filters), not the full dataset if it's larger.
Filters
Metric
View
A chart of recalls grouped by month.
Download CSVSummary (Year to date)
- 1,956 recalls have been announced year to date.
- Oct 2026 was 4% higher than the previous complete period (Sep 2026: 209).
- The highest complete period was Jun 2026 (300).
- Nov 2026 is incomplete and not included in the figures above.
- Complete data
- Incomplete
A bar chart of the total number of recalls in this dataset by recall class.
| Class | Recalls |
|---|---|
| Class II | 24,509 |
| Class I | 9,872 |
| Class III | 2,932 |
| Not Yet Classified | 2 |
| Class | Recalls |
|---|---|
| Class II | 24,509 |
| Class I | 9,872 |
| Class III | 2,932 |
| Not Yet Classified | 2 |
FDA Recall TerminatedTerminated: September 9, 2020Historical recordClass II
Anastrozole Tablets, USP, 1 mg, a) 30-count (NDC 68001-155-04) and 1000-count (NDC 68001-155-08) bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories
- Reason
- GMP Deviations: Potential cross contamination due to cleaning procedure failure.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: February 19, 2023Historical recordClass II
Losartan Potassium Tablets, USP. 50 mg. NDC# 0904-6390-61. Rx only. 100 count Unit Dose Cartons. Manufactured by Major Pharmaceuticals 17177 N. Laurel Park Drive Suite 233, Livonia, MI 48152.
- Reason
- CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: February 19, 2020Historical recordClass II
Losartan Potassium, 100 mg tablets, 90 count bottle, NDC 60429-318-90
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: February 19, 2020Historical recordClass II
Losartan Potassium, 50 mg tablets, 1000 count bottle, NDC 60429-317-10
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: February 19, 2020Historical recordClass II
Losartan Potassium, 50 mg tablets, 90 count bottle, NDC 60429-317-90
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: February 19, 2020Historical recordClass II
Losartan Potassium, 50 mg tablets, 30 count bottle, NDC 60429-317-30
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: October 26, 2021Historical recordClass II
Losartan Potassium andHydrochlorothiazide Tablets 100 mg/25 mg 90 tablets, USP Rx Only, Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-052-10
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: October 26, 2021Historical recordClass II
Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-051-10
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: October 26, 2021Historical recordClass II
Losartan Potassium and Hydrochlorothiazide Tablets, USP 50 mg/12.5 mg 90 Tablets, USP Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-050-10
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: October 26, 2021Historical recordClass II
Losartan Potassium Tablets 50 mg 1000 Tablets, USP Rx Only Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-045-44
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: October 26, 2021Historical recordClass II
Losartan Potassium Tablets, USP 50 mg 90 tablets Rx Only Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-045-10
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall OngoingHistorical recordClass II
LOSARTAN POTASSIUM 100 mg TABLET BULK 90 count bottles, NDC 00591-3747-00
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall OngoingHistorical recordClass II
LOSARTAN POTASSIUM 50 mg TABLET BULK 90 count bottles and 1000 count bottles, NDC 00591-3746-00
- Reason
- CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
- Published
- July 17, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: June 2, 2020Historical recordClass I
Hydromorphone HCl in 0.9% sodium chloride, 0.5mg per mL, 1 mL in 3mL BD Syringe, PharMEDium 913 N Davis Ave Cleveland, MS 38732, 800-523-7749, NDC 61553-352-78
- Reason
- Incorrect Product Formulation; Firm's customer resource center (CRC) statement indicates that the product is sulfite free, however the product is produced with a raw material that contains sulfite
- Published
- July 10, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: January 28, 2021Historical recordClass III
Testosterone Topical Solution 30mg of testosterone per pump actuation * each actuation delivers 1.5 mL of solution Total contents: 110 mL to deliver 90 mL, Manufactured by: Cipla Ltd, Verna Goa, India Manufactured for: Cipla USA, Inc., Sunrise, FL 33323 NDC 69097-363-44
- Reason
- Defective Container; actuator may improperly function and affect dose delivery.
- Published
- July 10, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: August 8, 2019Historical recordClass III
Esterified Estrogens & Methyltestosterone Tablets, USP 1.25 mg/2.5 mg, 100-count bottles, Rx Only, Manufactured by: Ammeal Pharmaceuticals of NY Hauppauge, NY 11788 Distributed by: Seton Pharmaceuticals Manasquan, NJ 08736, NDC 13925-172-01
- Reason
- Subpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone tablets.
- Published
- July 10, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: August 8, 2019Historical recordClass III
Esterified Estrogens & Methyltestosterone Tablets, USP 0.625 mg/1.25 mg, 100-count bottles, Rx Only, Manufactured by: Ammeal Pharmaceuticals of NY Hauppauge, NY 11788 Distributed by: Seton Pharmaceuticals Manasquan, NJ 08736, NDC 13925-171-01
- Reason
- Subpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone tablets.
- Published
- July 10, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: September 30, 2020Historical recordClass II
Pramipexole Dihydrochloride Tablets, 1.0 mg, 30 Tablets (6 tablets per blister card), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217 NDC Blister Card: 68084-982-95; NDC Carton: 68084-982-25
- Reason
- GMP Deviations; possible cross contamination of product due to cleaning procedure failure.
- Published
- July 3, 2019
- Distribution
- Nationwide
FDA Recall TerminatedTerminated: September 30, 2020Historical recordClass II
Pramipexole Dihydrochloride Tablets, 0.5 mg, 30 Tablets (6 tablets per blister card), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217 NDC Blister Card: 68084-974-95; NDC Carton: 68084-974-25
- Reason
- GMP Deviations; possible cross contamination of product due to cleaning procedure failure.
- Published
- July 3, 2019
- Distribution
- Nationwide
Data last updated:
Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions. Read the full medical disclaimer.